Clinical Microbiology Newsletter, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
The Lancet Microbe, Год журнала: 2024, Номер unknown, С. 100947 - 100947
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
37
Antibiotics, Год журнала: 2024, Номер 13(9), С. 870 - 870
Опубликована: Сен. 11, 2024
Phage therapy, the use of bacteriophages (phages) to treat bacterial infections, is regaining momentum as a promising weapon against rising threat multidrug-resistant (MDR) bacteria. This comprehensive review explores historical context, modern resurgence phage and phage-facilitated advancements in medical technological fields. It details mechanisms action applications phages treating MDR particularly those associated with biofilms intracellular pathogens. The further highlights innovative uses vaccine development, cancer gene delivery vectors. Despite its targeted efficient approach, therapy faces challenges related stability, immune response, regulatory approval. By examining these areas detail, this underscores immense potential remaining hurdles integrating phage-based therapies into practices.
Язык: Английский
Процитировано
16
BMC Microbiology, Год журнала: 2025, Номер 25(1)
Опубликована: Янв. 13, 2025
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a severe threat for human health and urgently needs new therapeutic approaches. Lytic bacteriophages (phages) are promising clinically viable options against CRKP. We attempted to isolate lytic phages CRKP of sequence type 11 capsular 64 (ST11-KL64), the predominant in China. recovered phage from sewage collected at wastewater treatment station Sichuan province, obtained genome this found that it distinct all known with highest overall DNA similarity (12.5%, 16% coverage 78.4% identity) vB_EcoM_PHB05 (accession no. NC_052652) ICTV. This represents novel viral genus subfamily Stephanstirmvirinae, which we proposed "Sichuanvirus" as name. has narrow host range lyse specific KL64 Klebsiella. no genes referring antimicrobial resistance, virulence, lysogen stable wide pH temperatures. also three bacterial mutants resistant performed sequencing them. therefore discovered interruption polysaccharide biosynthesis-related gene wcaJ by insertion sequences mediated resistance phage. characterized "Sichuanvirus", suitable therapy. The discovery expands arsenal
Язык: Английский
Процитировано
2
Nature Reviews Methods Primers, Год журнала: 2025, Номер 5(1)
Опубликована: Фев. 13, 2025
Процитировано
2
Infectious Diseases, Год журнала: 2024, Номер 56(10), С. 785 - 817
Опубликована: Июль 17, 2024
The increasing global incidence of multidrug-resistant (MDR) bacterial infections threatens public health and compromises various aspects modern medicine. Recognising the urgency this issue, World Health Organisation has prioritised development novel antimicrobials to combat ESKAPEE pathogens. Comprising
Язык: Английский
Процитировано
10
Journal of Intensive Care, Год журнала: 2024, Номер 12(1)
Опубликована: Ноя. 1, 2024
Abstract The increase in the incidence of antibiotic-resistant bacteria poses a global public health threat. According to 2019 WHO report, approximately 1.27 million deaths were attributed bacteria, with many cases linked specific bacterial species, such as drug-resistant Pseudomonas aeruginosa and Staphylococcus aureus. By 2050, number caused by these is predicted surpass that cancer. In response this serious situation, phage therapy, an alternative antibiotic treatment, has gained attention. Phage therapy involves use viruses target treat infections. This method proven effective multiple clinical cases, particularly for patients severe infections multidrug-resistant bacteria. For example, there are reports systemic Acinetobacter who recovered following administration infected panresistant cured therapy. A key feature its high specificity. Phages infect only eliminate them. However, specificity can also be disadvantage, careful selection appropriate needed. Additionally, develop resistance phages, potentially reducing treatment effectiveness over time. Efforts underway select, combine, improve phages address challenges. Belgium, national bank been established, United States, University California, San Diego, founded Innovative Applications Therapeutics (IPATH), marking significant progress toward application country. As result, emerging component personalized medicine, offering new option against important life-saving treatments infections, conjunction antibiotics could enhance therapeutic outcomes. Continued research development provide hope more future.
Язык: Английский
Процитировано
10
Cell, Год журнала: 2024, Номер unknown
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
9
Nature Communications, Год журнала: 2024, Номер 15(1)
Опубликована: Ноя. 28, 2024
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application mainly limited to personalized due the narrow host range of individual phages. While phage cocktails targeting all possible receptors could theoretically confer broad coverage, extensive diversity bacteria and complexity phage-phage interactions render this approach challenging. Here, using screening protocols identifying "complementarity groups" phages non-redundant receptors, we generate effective, broad-range that prevent emergence resistance. We also discover characteristic between complementarity groups particular antibiotic classes, facilitating prediction phage-antibiotic as well interactions. Using strategy, create three cocktails, each demonstrating efficacy against ≥96% 153 Pseudomonas aeruginosa clinical isolates, including biofilm cultures, demonstrate comparable in an vivo wound infection model. similarly develop effective Staphylococcus aureus their utility combined polymicrobial (mixed P. aeruginosa/S. aureus) highlighting applicability approach. These studies establish blueprint development broad-spectrum paving way off-the-shelf phage-based therapeutics combat infections. The infections Kim et al. identify use present combinations.
Язык: Английский
Процитировано
8
Emerging Microbes & Infections, Год журнала: 2025, Номер 14(1)
Опубликована: Янв. 7, 2025
Serratia marcescens (S. marcescens) commonly induces refractory infection due to its multidrug-resistant nature. To date, there have been no reports on the application of phage treatment for S. infection. This study was conducted explore feasibility in treating by collaborating with a 59-year-old male patient pulmonary marcescens. Our experiments included three domains: i) selection appropriate phage, ii) verification efficacy and safety selected iii) confirmation phage-bacteria interactions. results showed that Spe5P4 is Treatment good efficacy, manifested as amelioration symptoms, hydrothorax examinations, chest computed tomography findings. Phage did not worsen hepatic renal function, immunity-related indices, or indices routine blood examination. It induce deteriorate drug resistance involved antibiotics. Importantly, adverse events were reported during follow-up periods. Thus, satisfactory safety. Finally, we found increase bacterial load, cytotoxicity, virulence, marcescens, indicating interactions between which are useful future against work provides evidence working basis further infections. We also provided methodological investigating clinical infections future.
Язык: Английский
Процитировано
1
Microorganisms, Год журнала: 2025, Номер 13(1), С. 100 - 100
Опубликована: Янв. 7, 2025
Phage therapy, which involves the use of bacteriophages (phages) to combat bacterial infections, is emerging as a promising approach address escalating threat posed by multidrug-resistant (MDR) bacteria. This brief review examines historical background and recent advancements in phage research, focusing on their genomics, interactions with host bacteria, progress medical biotechnological applications. Additionally, we expose key aspects mechanisms action, therapeutic uses considerations treating MDR infections are discussed, particularly context related virus-bacteria interactions.
Язык: Английский
Процитировано
1